Contineum Therapeutics, Inc.
CTNM
$11.43
-$0.10-0.87%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 2.70% | 15.53% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -1.23% | 14.62% | |||
| Operating Income | 1.23% | -14.62% | |||
| Income Before Tax | 4.62% | -18.48% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 4.62% | -18.48% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 4.62% | -18.48% | |||
| EBIT | 1.23% | -14.62% | |||
| EBITDA | 1.23% | -14.67% | |||
| EPS Basic | 21.16% | -7.93% | |||
| Normalized Basic EPS | 21.15% | -7.91% | |||
| EPS Diluted | 21.16% | -7.93% | |||
| Normalized Diluted EPS | 21.15% | -7.91% | |||
| Average Basic Shares Outstanding | 20.98% | 9.77% | |||
| Average Diluted Shares Outstanding | 20.98% | 9.77% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||